US2020087402A1PendingUtilityA1
Sialylated Glycoproteins
Assignee: MOMENTA PHARMACEUTICALS INCPriority: Oct 16, 2013Filed: Nov 19, 2019Published: Mar 19, 2020
Est. expiryOct 16, 2033(~7.3 yrs left)· nominal 20-yr term from priority
C07K 16/2848C07K 2317/41C07K 2317/21A61K 2039/505C07K 16/00A61P 7/00C07K 16/06A61K 39/39516
65
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Pharmaceutical preparations containing polypeptides having particular sialylation patterns, and methods for the treatment of immune-related thrombocytopenia with such preparations, are described.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A pharmaceutical preparation comprising sialylated IVIG, wherein at least 65% of branched glycans are sialylated on both the on both the α 1,3 arm and the α 1,6 arm by way of NeuAc-α 2,6-Gal terminal linkages; at least 60% of the branched glycans on the Fab domain are sialylated on both the on both the α 1,3 arm and the α 1,6 arm by way of NeuAc-α 2,6-Gal terminal linkages; and at least 80% of the branched glycan on the Fc domain are sialylated on both the on both the α 1,3 arm and the α 1,6 arm by way of NeuAc-α 2,6-Gal terminal linkages.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.